You are here: Welcome to the MPKB » Welcome to the MPKB » Marshall Protocol
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:mp [03.13.2019] – [Data] sallieqhome:mp [04.02.2020] – [Marshall Protocol] sallieq
Line 3: Line 3:
  
 ====== Marshall Protocol ====== ====== Marshall Protocol ======
 +
 +<relatedarticles> [[home:starting:usingforum:home_help_using_forums:a_a_href|5 key elements of MP]] </article>
  
 This document is a one-article summary of key issues related to the Marshall Protocol, especially those relevant to physicians.  Many of the topics covered here are reviewed in greater depth throughout the Knowledge Base.  This document is a one-article summary of key issues related to the Marshall Protocol, especially those relevant to physicians.  Many of the topics covered here are reviewed in greater depth throughout the Knowledge Base. 
Line 250: Line 252:
 Olmesartan will need to be [[home:mp:break:olmesartan#stopping_olmesartan|weaned very gradually]]. Note that the immune response may remain activated for a period of time even after discontinuing olmesartan. Patients who stop olmesartan are terminating their recovery. Olmesartan will need to be [[home:mp:break:olmesartan#stopping_olmesartan|weaned very gradually]]. Note that the immune response may remain activated for a period of time even after discontinuing olmesartan. Patients who stop olmesartan are terminating their recovery.
  
 +
 +{{tag>MP summary}}  
 ===== Data ===== ===== Data =====
  
-[[home:patients:cohort_statistics#later_information_2013|Success rates for various Dx, compiled in 2013]]+[[home:patients:cohort_statistics#later_information_2013|Success rates for various Dx, compiled in 2013]]  (extract below)
  
 [[home:food:aim_health:aging|Olmesartan research]] [[home:food:aim_health:aging|Olmesartan research]]
  
 +==== Recovery figures ====
 +
 + TOTALS: 864 members;573 report success; 119 report no success; and for 172 results are not clear.
 +
 +SUCCESS RATES: Over all success rate 66.32% Over all unsuccessful 13.77% Over all unsure 19.91%
 +
 +Sarcoidosis success 75.8%
 +
 +Chronic Fatigue Syndrome success 60.1%
 +
 +Lyme disease success 66.9%
 +
 +Rheumatoid arthritis success 69.2%
 +
 +Fibromyalgia success 64.2%
 +
 +All Other Th1 disease success 59.8% 
 ===== Notes and comments ===== ===== Notes and comments =====
  
home/mp.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.